BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.131_2629
Abstract: sultant Advisory Role: Acerta Pharma, Bayer, Celgene, Gilead Sciences, Janssen, Novartis, Roche, and Sandoz; Honoraria: Bayer, Celgene, Gilead Sciences, Janssen, and Roche; Research Funding: Celgene, Janssen, Mundipharma, and Roche; Other Remuneration: Travel, accommodations and expenses… read more here.
Keywords: roche; verastem bms; msd johnson; bms msd ... See more keywords